Drugs

Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book

Photo from Erman Akkus/X

Apr 4, 2024, 13:34

Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“NSCLC and anti-EGFR treatments from the ASCO Educational Book

Early stage-adjuvant

Gefitinib, icotinib > high DFS, no OS benefit (ADJUVANT/CTONG 1104, IMPACT and EVIDENCE)
Osimertinib > high DFS, OS (ADAURA)
Ongoing trials: ADAURA2, TARGET
Ongoing trial in neoadjuvant: NeoADAURA
+ Anti-ALK, IO for driver mutation

Unresectable, after defitive treatment

Osimertinib> high PFS (LAURA, ongoing)
Ongoing trials: PACIFIC4, HORIZON-01

Metastatic

1G, 2G and new TKIs (in figures below)

Resistance mechanisms and strategies to overcome (in figures below).”

Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book

View additional information.
Source: Erman Akkus/X

ADAURA ADAURA2 ADJUVANT/CTONG 1104 Ankara University anti-EGFR treatments ASCO ASCO Educational Book cancer Erman Akkus EVIDENCE Gefitinib HORIZON-01 icotinib impact NeoADAURA non small cell lung cancer NSCLC OncoDaily Oncology osimertinib PACIFIC4 TARGET TKIs

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage